Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease

Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease

Background: Low anti-tumor necrosis factor α (TNFα) serum concentrations may result in lack of treatment response in patients with inflammatory bowel disease. We determined the anti-TNFα drug concentrations in patients with inflammatory bowel disease and investigated whether or not subtherapeutic dr...

Full description

Bibliographic Details
Main Authors: Arne Carlsen, Roald Omdal, Kristian Øgreid Leitao, Kjetil Isaksen, Anne Kristine Hetta, Lars Normann Karlsen, Lars Aabakken, Nils Bolstad, David Warren, Knut E.A. Lundin, Tore Grimstad
Format: Article
Language:English
Published: SAGE Publishing 2018-03-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/1756284818759930

Internet

https://doi.org/10.1177/1756284818759930

Similar Items